Lexology November 21, 2021
Sheppard Mullin Richter & Hampton LLP

The Food and Drug Administration recently sought comments on the role of transparency for artificial intelligence and machine learning-enabled medical devices. The FDA invited comments in follow up to a recent workshop on the topic.

The workshop was part of a series of efforts the FDA has had in this space. These include its Digital Health Center of Excellence and a five-part Action Plan for AI and machine-learning enabled medical devices. As part of the action plan, the FDA indicated it wants to issue guidance on software learning over time and help the industry be “patient-centered.” In other words, that companies be transparent when using AI and machine learning-enabled software with patients. These initiatives are especially important given the increase...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Technology
March Fundraising Roundup: 7 Provider Tech Startups That Closed Rounds This Month
Google DeepMind unveils ‘superhuman’ AI system that excels in fact-checking, saving costs and improving accuracy
Katie Couric Talks Colon Cancer, Health Equity And AI
5 tips on AI adoption from a frontline physician champion
Survey of Oncologists Finds Agreement, Concerns Over AI Use

Share This Article